-- 石药集团（HKG:1093）周一在香港交易所发布公告称，其注射用西罗莫司（白蛋白结合型）的Ib/III期临床研究已达到预设的主要疗效终点，显示出具有统计学意义的显著差异和明显的临床获益。 该药物由石药集团旗下子公司石药中奇药业科技（石家庄）有限公司研发，用于治疗晚期恶性血管周上皮样细胞肿瘤。
Related Articles
Australia
Yum! Brands Expected to Deliver 'Low-Controversy' Q1, RBC Says
Yum! Brands (YUM) is expected to report a "relatively low-controversy" Q1, RBC Capital Markets said Sunday in a report.The Taco Bell US business likely continued to outperform compared with the broader quick-service category, with buy-side same-store sales expectations at least a few hundred basis points above the sell-side's 4.9% estimate, the report said.For KFC International, a key focus in the earnings call will be any impact on international demand from higher fuel prices due to the conflict in the Middle East, the report said.RBC said it doesn't expect a "meaningful" update on Pizza Hut's strategic review with the bidding process likely still underway.RBC maintained its sector perform rating on Yum! stock with a $165 price target.Q1 results are due April 29.Price: $162.74, Change: $-0.05, Percent Change: -0.03%
$YUM
Australia
Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule
Cosmos Health (COSM) said Monday that it has completed the first phase execution of its Liv18 liver health supplement ahead of schedule.Production of Liv18 is expected to commence this month, with initial market rollout to follow shortly thereafter, the company said.Cosmos said that based on planned investments in advertising, customer acquisition, and business development, along with early US commercial traction from its other products, Liv18 is expected to generate over $5 million in annual revenue, with gross margins of about 75%.Shares of the company were down more than 6% in Monday's trading.Price: $0.38, Change: $-0.03, Percent Change: -6.47%
$COSM
Australia
Lithium Americas Faces Key Year at Thacker Pass, Wedbush Says
Lithium Americas (LAC) is facing a defining execution year at Thacker Pass, which has evolved from a mining development project into a national security asset, Wedbush Securities said in a Monday note."We see FY26 as a key year for the Thacker Pass buildout with the favorable geopolitical backdrop for domestic lithium production," the report said.The note said construction momentum is building at the project and is fully funded through first production. It said Thacker Pass is underpinned among others by the world's largest known measured lithium resource, a $2.23 billion Department of Energy loan, and a GM joint venture with a 20-year offtake deal.Wedbush kept its neutral rating and $8 price target, saying that execution risk remains the primary overhang.Price: $5.06, Change: $+0.22, Percent Change: +4.44%
$GM$LAC